Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Linagliptin

FDA-approved product (tablet, oral), marketed as Linagliptin, Tradjenta.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Linagliptin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diabetes mellitus
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Dipeptidyl peptidase 4 (dpp-4) inhibitors
FDA pharmacologic class
Dipeptidyl Peptidase 4 Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae40.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Linagliptin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Linagliptin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Investigation of the Metabolism and Pharmacokinetics of 10 mg [14C] BI 1356 Administered Orally Compared to 5 mg [14C] BI 1356 Administered Intravenously in Healthy Male Volunteers

    NCT02183610 · start 2006-07

    Registered record
    Registry ID
    NCT02183610
    Conditions
    Healthy
    Interventions
    [14C] BI 1356 as oral (p.o.) solution; [14C] BI 1356 solution for i.v. infusion
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-07
    Completion
    Not recorded
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Intervention[14C] BI 1356 as oral (p.o.) solution; [14C] BI 1356 solution for i.v. infusion
    PhasePhase 1
    Registry statusCompleted

  • Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS

    NCT02180503 · start 2005-08

    Registered record
    Registry ID
    NCT02180503
    Conditions
    Healthy
    Interventions
    BI 1356 BS PIB - low dose; BI 1356 BS tablet - low dose; BI 1356 BS PIB - high dose; BI 1356 BS tablet - high dose; BI 1356 BS tablet - high dose with food
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-08
    Completion
    Not recorded
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionBI 1356 BS PIB - low dose; BI 1356 BS tablet - low dose; BI 1356 BS PIB - high dose; BI 1356 BS tablet - high dose +1 more
    PhasePhase 1
    Registry statusCompleted

  • Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes

    NCT02183415 · start 2005-08

    Registered record
    Registry ID
    NCT02183415
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    BI 1356 BS, low dose; BI 1356 BS, medium dose; BI 1356 BS, high dose; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-08
    Completion
    Not recorded
    Enrolment
    77

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionBI 1356 BS, low dose; BI 1356 BS, medium dose; BI 1356 BS, high dose; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 Diabetes

    NCT02183350 · start 2005-04

    Registered record
    Registry ID
    NCT02183350
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    BI 1356 BS - single rising dose; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-04
    Completion
    Not recorded
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionBI 1356 BS - single rising dose; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS Administered to Healthy Male Subjects

    NCT02173665 · start 2004-10

    Registered record
    Registry ID
    NCT02173665
    Conditions
    Healthy
    Interventions
    BI 1356 BS - Powder in bottle (PIB); BI 1356 BS - Tablet; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-10
    Completion
    Not recorded
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionBI 1356 BS - Powder in bottle (PIB); BI 1356 BS - Tablet; Placebo
    PhasePhase 1
    Registry statusCompleted